# GCC Thrombus Treatment Market > GCC Thrombus Treatment Market Research Report By Type (Atrial Thrombus, Venous Thrombus) and By Treatment (Medical Therapy, Surgery, Others) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 6.57% - **2024:** $ 2,013.5 Million - **2025:** $ 2,145.79 Million - **2035:** $ 4,055.4 Million - **Key Players:** Bayer AG (DE), Bristol-Myers Squibb Company (US), Johnson & Johnson (US), Roche Holding AG (CH), Sanofi S.A. (FR), AstraZeneca PLC (GB), Pfizer Inc. (US), Merck & Co., Inc. (US) **Report ID:** MRFR/HC/51840-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/gcc-thrombus-treatment-market-53601 --- ## Market Summary ## **GCC Thrombus Treatment Market Overview** As per MRFR analysis, the GCC Thrombus Treatment Market Size was estimated at 1.97 (USD Billion) in 2023.The GCC Thrombus Treatment Market is expected to grow from 2.5(USD Billion) in 2024 to 5.5 (USD Billion) by 2035. The GCC Thrombus Treatment Market CAGR (growth rate) is expected to be around 7.431% during the forecast period (2025 - 2035). **Key GCC Thrombus Treatment Market Trends Highlighted** A rise in cardiovascular disorders and increased public awareness of thrombotic problems are driving many significant trends in the GCC thrombus treatment market. The expansion of thrombus treatment choices is mostly driven by the region's health authorities' efforts to improve healthcare services and invest in cutting-edge medical technology. In order to create opportunities for new treatments and technologies, governments in the GCC are concentrating on projects to upgrade healthcare infrastructure, one of which is encouraging the use of thrombus treatment options. Minimally invasive procedures have been more popular in recent years because both patients and medical professionals like treatments that require less recovery time and fewer consequences. The market is also being shaped by the development of innovative medication therapies and the incorporation of cutting-edge imaging technology. Hospitals and pharmaceutical companies are increasingly working together in the area to develop better treatment options that can improve patient outcomes. The GCC Thrombus Treatment Market has a lot of opportunities, particularly in the field of preventative care. Preventive efforts, such awareness campaigns and early detection programs, are receiving a lot of attention because lifestyle-related diseases are on the rise. The increase in healthcare spending in GCC countries indicates a desire to incorporate cutting-edge medical solutions, which will foster an environment that is conducive to market growth. Furthermore, telemedicine services have proliferated, making it simpler for patients to access choices for thrombus control and therapy. **** Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **GCC Thrombus Treatment Market Drivers** **Rising Incidence of Cardiovascular Diseases** The GCC region has witnessed a concerning rise in cardiovascular diseases, which are pivotal contributors to thrombus formation. According to health statistics published by the Ministry of Health in Saudi Arabia, cardiovascular diseases account for approximately 40% of all deaths annually in the kingdom, indicating a significant health burden. This escalating incidence necessitates effective thrombus treatments, driving the growth of the GCC [Thrombus Treatment Market](../../../reports/thrombus-treatment-market-11453). Furthermore, the Emirates Cardiac Society has reported an increase of around 10% in heart-related ailments over the past decade among adults, indicating a rising demand for therapeutic solutions. Established healthcare providers like King Faisal Specialist Hospital and Research Centre are enhancing their thrombus treatment protocols, emphasizing the importance of innovative therapies to address this health crisis, thereby supporting market growth in this sector. **Advancements in Medical Technology** Technological innovations play a crucial role in enhancing the efficacy of thrombus treatments in the GCC Thrombus Treatment Market. With significant investments from governments and private sectors, countries like the United Arab Emirates and Qatar are embracing cutting-edge technologies such as thrombectomy devices and advanced drug eluting stents. Research conducted by the Qatar University has showcased a 20% improvement in treatment outcomes using these modern devices compared to conventional methods. As a result, healthcare providers such as Hamad Medical Corporation are more inclined to invest in these advanced technologies, thereby fostering a competitive landscape that accelerates treatment advancements and fuels market growth. **Government Initiatives to Improve Healthcare Infrastructure** Governments within the GCC region are undertaking extensive initiatives to strengthen healthcare infrastructure, which is essential for the advancement of thrombus treatment services. The Qatar National Health Strategy aims to enhance the healthcare delivery system through various programs focusing on preventative care and chronic disease management. Reports indicate that healthcare expenditure in the GCC region is projected to grow by 7% annually, with allocations directed towards improving access to advanced medical treatments. Health entities like the Gulf Cooperation Council Health Ministerial Committee are actively involved in promoting awareness about thrombus-related conditions, actively driving investments in thrombus treatment options, subsequently propelling the growth trajectory of the GCC Thrombus Treatment Market. **GCC Thrombus Treatment Market Segment Insights** **Thrombus Treatment Market Type Insights** The GCC Thrombus Treatment Market exhibits a diverse landscape influenced by varying types of thrombus, primarily Atrial Thrombus and Venous Thrombus. Atrial Thrombus is particularly noteworthy due to its association with serious cardiovascular conditions, such as atrial fibrillation, which has been on the rise in the region. This increase is a direct reflection of lifestyle changes, a growing aging population, and underlying health conditions prevalent in the GCC area, creating a pressing need for effective treatment solutions. It captures a significant share of the overall thrombus treatment landscape, largely driven by advancements in medical technologies and increased awareness of cardiac health. On the other hand, Venous Thrombus emphasizes the critical role of understanding deep vein thrombosis and pulmonary embolism, which are becoming predominant health issues, particularly due to prolonged periods of immobility and sedentary lifestyles common in urban areas of the GCC. The heightened focus on healthcare infrastructure in GCC countries, underpinned by various national health initiatives, supports growth in this segment, as increased availability of diagnostic and therapeutic options lead to improved patient outcomes. These segments reflect robust growth potential, with ongoing Research and Development initiatives aimed at enhancing treatment efficacy and safety, reinforcing the significance and growth trajectory of the GCC Thrombus Treatment Market. In summary, the classification of thrombus treatment into these types illustrates the multifaceted nature of thrombus conditions, allowing for tailored healthcare solutions that address the unique health challenges faced by populations in the GCC. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Thrombus Treatment Market Treatment Insights** The GCC Thrombus Treatment Market encompasses a broad spectrum of treatment strategies that are crucial in managing thrombotic conditions effectively. In this market, Medical Therapy plays a pivotal role, as it primarily focuses on pharmacological interventions aimed at dissolving clots and preventing their formation, contributing significantly to patient outcomes across diverse demographics. Surgery also remains a vital approach, particularly in cases where medical therapy alone is insufficient, allowing for direct removal of thrombus and restoring blood flow, thus emphasizing the importance of advanced surgical techniques in the region. Furthermore, other treatments, which may include mechanical interventions or supportive therapies, also enhance patient care by addressing specific complications associated with thrombotic diseases. As the GCC region continues to invest in healthcare infrastructure and technological advancements, the market is poised for substantial growth, driven by rising awareness of thrombotic conditions, escalating healthcare expenditures, and an increase in the geriatric population. The GCC Thrombus Treatment Market data indicates a progressive shift toward innovative therapeutic approaches, spotlighting the blend of established surgical practices and emerging medical therapies in enhancing patient recovery and success rates. Overall, the growing adoption of these treatment strategies within the GCC underscores a commitment to improving health outcomes and managing thrombus effectively. **GCC Thrombus Treatment Market Key Players and Competitive Insights** The GCC Thrombus Treatment Market is experiencing significant growth due to an increasing prevalence of thromboembolic disorders, the rising aging population, and advancements in clinical practices. The competition in this market is characterized by the presence of key players striving to offer innovative treatment options, including pharmacological solutions and medical devices aimed at effectively managing thrombotic conditions. Companies are investing substantially in research and development to enhance their product offerings and meet the evolving needs of healthcare providers and patients. As the market is influenced by regulatory approvals, reimbursement policies, and healthcare spending patterns, stakeholders are actively analyzing competitive benchmarks to gain a foothold in an increasingly dynamic environment. Amgen has established a strong presence in the GCC Thrombus Treatment Market through its robust portfolio of products that target thromboembolic disorders. The company is recognized for its commitment to research and innovation, consistently introducing new therapeutic agents aimed at improving treatment outcomes. Amgen focuses on harnessing advanced biotechnology to develop effective solutions that address various thrombus-related complications. The strength of Amgen lies not only in its product lineup but also in its strategic partnerships within the healthcare ecosystem in the GCC region, allowing for a more comprehensive approach to thrombus management. Furthermore, through dedicated marketing and distribution channels, Amgen effectively reaches healthcare providers, ensuring that its therapies are accessible to patients in need. Boston Scientific also plays a vital role in the GCC Thrombus Treatment Market with a wide range of products and services aimed at endovascular and interventional therapies. The company is well-known for its cutting-edge medical devices such as stents and thrombectomy systems designed to manage thrombotic conditions efficiently. Boston Scientific’s strengths lie in its commitment to innovation, as evidenced by its significant investments in research and development, leading to the introduction of novel products tailored for the GCC market. The company actively pursues mergers and acquisitions to enhance its capabilities and broaden its market offerings, thereby solidifying its position in the region. Boston Scientific also emphasizes continuous collaboration with healthcare professionals to educate them on the latest procedures and technologies in thrombus treatment, ensuring improved patient care while maintaining a competitive edge in the marketplace. **Key Companies in the GCC Thrombus Treatment Market Include:** - Amgen - Boston Scientific - Bayer - Roche - Gilead Sciences - Johnson & Johnson - Medtronic - AstraZeneca - Merck & Co - Terumo Corporation - Bristol Myers Squibb - Sanofi - Novartis - AbbVie - Cardinal Health **GCC Thrombus Treatment****Market****Developments** Significant recent developments in the GCC Thrombus Treatment Market include a surge in demand for advanced therapeutic solutions, driven by the increasing prevalence of thromboembolic disorders in the region. Companies such as Amgen, Boston Scientific, and Bayer are investing in innovative therapies, enhancing patient outcomes. Meanwhile, mergers and acquisitions have been notable, with Johnson and Johnson acquiring a stake in emerging technologies that focus on thrombus management as of September 2023, indicating consolidation within this sector. The expansion of Medtronic and AstraZeneca's portfolios is also noteworthy, as they continue to innovate with new treatment modalities and devices. Recent data show that Gilead Sciences and Roche have reported substantial growth in their thrombus treatment revenues, reflective of the increasing healthcare expenditures across the GCC region, enhancing access to advanced medical therapies. Over the past two years, the regulatory environment has evolved, with countries such as the UAE and Saudi Arabia streamlining approval processes for new thrombus treatments, effectively accelerating market growth. Overall, these developments signify a transformative phase for the GCC Thrombus Treatment Market, emphasizing innovation, collaboration, and enhanced accessibility to care. **GCC Thrombus Treatment Market Segmentation Insights** **Thrombus Treatment Market Type Outlook** - Atrial Thrombus - Venous Thrombus **Thrombus Treatment Market Treatment Outlook** - Medical Therapy - Surgery - Others ## Market Drivers ### Growing Geriatric Population The demographic shift towards an aging population in the GCC is a crucial driver for the thrombus treatment market. Older adults are at a higher risk for thromboembolic disorders due to age-related physiological changes and comorbidities. As the population aged 65 and above continues to grow, the incidence of thrombus-related conditions is likely to rise correspondingly. This demographic trend necessitates an increase in healthcare services and treatment options tailored to older patients. Consequently, the thrombus treatment market is projected to experience a surge in demand, with estimates suggesting a potential increase in market value by 15% over the next decade, driven by this demographic shift. ### Advancements in Medical Technology Technological innovations in medical devices and pharmaceuticals are significantly influencing the thrombus treatment market. The introduction of minimally invasive procedures and advanced imaging techniques has improved the efficacy of thrombus management. For instance, the development of novel anticoagulants and thrombolytics has enhanced treatment outcomes, reducing recovery times for patients. In the GCC, hospitals are increasingly adopting these advanced technologies, which not only improve patient care but also attract more patients seeking state-of-the-art treatment options. The market is expected to expand as these technologies become more widely available, potentially increasing the market size by an estimated $500 million by 2030. ### Enhanced Healthcare Infrastructure The ongoing improvements in healthcare infrastructure across the GCC are positively impacting the thrombus treatment market. Governments in the region are investing heavily in healthcare facilities, technology, and training for medical professionals. This investment is likely to enhance the availability and accessibility of thrombus treatment options. With better-equipped hospitals and clinics, patients are more likely to receive timely and effective care. The expansion of healthcare services is expected to lead to a 10% increase in the number of procedures performed annually, thereby driving market growth. Additionally, the establishment of specialized centers for thrombus treatment is anticipated to further bolster the market. ### Rising Prevalence of Lifestyle Diseases The increasing prevalence of lifestyle-related diseases in the GCC is a significant driver for the thrombus treatment market. Conditions such as obesity, diabetes, and hypertension are known risk factors for thromboembolic disorders. As lifestyle diseases become more common, the demand for effective thrombus treatment options is likely to rise. Public health initiatives aimed at combating these lifestyle diseases are also expected to contribute to increased screening and treatment for thrombus conditions. The market could see a growth rate of approximately 8% over the next five years, as healthcare systems adapt to address the rising burden of lifestyle-related health issues. ### Increasing Awareness of Thrombus Conditions The rising awareness regarding thrombus-related conditions is a pivotal driver for the thrombus treatment market. Educational campaigns and health initiatives are increasingly focusing on the risks associated with thromboembolic disorders. This heightened awareness is likely to lead to earlier diagnosis and treatment, thereby expanding the patient base. In the GCC region, healthcare providers are actively engaging in community outreach programs to inform the public about symptoms and risk factors. As a result, the demand for effective treatment options is expected to grow. Furthermore, the market is projected to witness a compound annual growth rate (CAGR) of approximately 7% over the next five years, driven by this increased awareness and proactive healthcare measures. ## Future Outlook The [Thrombus Treatment Market](https://www.marketresearchfuture.com/reports/thrombus-treatment-market-11453) is projected to grow at 6.57% CAGR from 2025 to 2035, driven by technological advancements, increasing prevalence of thrombotic disorders, and enhanced healthcare infrastructure. **New opportunities:** - Development of telehealth platforms for remote thrombus monitoring - Investment in AI-driven diagnostic tools for early thrombus detection - Expansion of outpatient treatment facilities for thrombus management By 2035, the thrombus treatment market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Type: Atrial Thrombus (Largest) vs. Venous Thrombus (Fastest-Growing) The GCC thrombus treatment market is primarily dominated by the Atrial Thrombus segment, which holds the largest market share owing to the prevalent cases of atrial fibrillation and the increasing adoption of advanced therapeutic options. The Venous Thrombus segment, while smaller, is swiftly gaining traction, propelled by heightened awareness and improvements in treatment methodologies. In recent years, the growth trends within the Atrial Thrombus segment have been bolstered by technological advancements and favorable regulatory frameworks. Meanwhile, the Venous Thrombus segment is emerging rapidly, driven by rising incidences of venous thromboembolism and the introduction of innovative therapies addressing this condition. This dynamic shift indicates a balanced evolution within the market, catering to diverse patient needs and treatment approaches. Atrial Thrombus (Dominant) vs. Venous Thrombus (Emerging) The Atrial Thrombus segment remains the dominant force in the GCC thrombus treatment market, characterized by a significant number of treatment options and established protocols that cater to patients with atrial fibrillation. It benefits from extensive clinical literature supporting its efficacy and a strong endorsement from healthcare providers. In contrast, the Venous Thrombus segment is considered emerging, with rapid advancements in treatment technologies and growing recognition of venous thromboembolism's impact on public health. This segment is characterized by the development of new anticoagulants and minimally invasive procedures, making it increasingly relevant for healthcare systems aiming to improve patient outcomes. ### By Treatment: Medical Therapy (Largest) vs. Surgery (Fastest-Growing) In the GCC thrombus treatment market, Medical Therapy holds the largest share, reflecting its crucial role in managing thrombotic conditions through pharmacological interventions. This segment's dominance underscores the reliance on medications to dissolve blood clots and prevent their formation, making it a preferred choice among healthcare practitioners and patients alike. On the other hand, the Surgery segment is emerging as the fastest-growing area within the market. Factors driving this growth include advancements in surgical techniques and technologies, which enhance the efficacy and safety of procedures. Increased awareness and diagnosis of thrombotic disorders also contribute to a rise in surgical interventions, thus underscoring its expanding significance in the treatment landscape. Medical Therapy (Dominant) vs. Surgery (Emerging) Medical Therapy serves as the dominant approach in the GCC thrombus treatment market, characterized by a wide range of anticoagulants and thrombolytic agents designed to manage and treat thromboembolic events effectively. Its established presence is due to the extensive research supporting effectiveness and patient compliance. Conversely, the Surgery segment is emerging, focused on procedures like thrombectomy and catheter-directed therapies, which are increasingly preferred due to minimally invasive techniques and quick recovery rates. The evolution of surgical tools and technologies positions this segment as increasingly vital, attracting interest from healthcare providers looking for comprehensive treatment options beyond pharmacotherapy. ### Thrombus Treatment Market Treatment Insights Thrombus Treatment Market Treatment Insights The GCC Thrombus Treatment Market encompasses a broad spectrum of treatment strategies that are crucial in managing thrombotic conditions effectively. In this market, Medical Therapy plays a pivotal role, as it primarily focuses on pharmacological interventions aimed at dissolving clots and preventing their formation, contributing significantly to patient outcomes across diverse demographics. Surgery also remains a vital approach, particularly in cases where medical therapy alone is insufficient, allowing for direct removal of thrombus and restoring blood flow, thus emphasizing the importance of advanced surgical techniques in the region. Furthermore, other treatments, which may include mechanical interventions or supportive therapies, also enhance patient care by addressing specific complications associated with thrombotic diseases. As the GCC region continues to invest in healthcare infrastructure and technological advancements, the market is poised for substantial growth, driven by rising awareness of thrombotic conditions, escalating healthcare expenditures, and an increase in the geriatric population. ## Competitive Benchmarking The thrombus treatment market is currently characterized by a dynamic competitive landscape, driven by increasing incidences of thromboembolic disorders and a growing emphasis on innovative treatment solutions. Key players such as Bayer AG (DE), Bristol-Myers Squibb Company (US), and Johnson & Johnson (US) are strategically positioned to leverage their extensive research and development capabilities. Bayer AG (DE) focuses on expanding its portfolio of anticoagulants, while Bristol-Myers Squibb Company (US) emphasizes partnerships to enhance its therapeutic offerings. Johnson & Johnson (US) is investing in digital health technologies to improve patient outcomes, collectively shaping a competitive environment that prioritizes innovation and patient-centric solutions.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The market appears moderately fragmented, with several players vying for market share. However, the collective influence of major companies is significant, as they drive advancements in treatment modalities and establish robust distribution networks, thereby enhancing their competitive positioning. In October Bayer AG (DE) announced a strategic partnership with a leading digital health firm to develop a new platform aimed at improving patient adherence to anticoagulant therapies. This move is likely to enhance Bayer's market presence by integrating technology into treatment regimens, thereby addressing a critical challenge in thrombus management. The partnership underscores Bayer's commitment to innovation and patient engagement, which may yield long-term benefits in terms of market share and brand loyalty. In September Bristol-Myers Squibb Company (US) launched a new clinical trial for its novel anticoagulant, which aims to provide improved efficacy and safety profiles compared to existing therapies. This initiative reflects the company's focus on research-driven growth and its intent to capture a larger segment of the thrombus treatment market. The trial's outcomes could potentially redefine treatment standards and enhance the company's competitive edge. In August Johnson & Johnson (US) unveiled a new digital platform designed to facilitate remote monitoring of patients undergoing thrombus treatment. This initiative is indicative of the company's strategic pivot towards digital health solutions, which may enhance patient engagement and adherence. By integrating technology into its treatment protocols, Johnson & Johnson is likely to differentiate itself in a crowded market, appealing to both healthcare providers and patients. As of November current trends in the thrombus treatment market include a pronounced shift towards digitalization, sustainability, and the integration of artificial intelligence in treatment protocols. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is expected to evolve, with a greater emphasis on innovation and technology rather than solely on price. Companies that can effectively leverage these trends will likely secure a more robust market position, ensuring long-term sustainability and growth. ## Recent News & Developments Significant recent developments in the GCC Thrombus Treatment Market include a surge in demand for advanced therapeutic solutions, driven by the increasing prevalence of thromboembolic disorders in the region. Companies such as Amgen, Boston Scientific, and Bayer are investing in innovative therapies, enhancing patient outcomes. Meanwhile, mergers and acquisitions have been notable, with Johnson and Johnson acquiring a stake in emerging technologies that focus on thrombus management as of September 2023, indicating consolidation within this sector. The expansion of Medtronic and AstraZeneca's portfolios is also noteworthy, as they continue to innovate with new treatment modalities and devices. Recent data show that Gilead Sciences and Roche have reported substantial growth in their thrombus treatment revenues, reflective of the increasing healthcare expenditures across the GCC region, enhancing access to advanced medical therapies. Over the past two years, the regulatory environment has evolved, with countries such as the UAE and Saudi Arabia streamlining approval processes for new thrombus treatments, effectively accelerating market growth. Overall, these developments signify a transformative phase for the GCC Thrombus Treatment Market, emphasizing innovation, collaboration, and enhanced accessibility to care. ## Report Scope | MARKET SIZE 2024 | 2013.5(USD Million) | | --- | --- | | MARKET SIZE 2025 | 2145.79(USD Million) | | MARKET SIZE 2035 | 4055.4(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.57% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Bayer AG (DE), Bristol-Myers Squibb Company (US), Johnson & Johnson (US), Roche Holding AG (CH), Sanofi S.A. (FR), AstraZeneca PLC (GB), Pfizer Inc. (US), Merck & Co., Inc. (US) | | Segments Covered | Type, Treatment | | Key Market Opportunities | Emergence of innovative thrombolytic agents and minimally invasive procedures enhances treatment options in the thrombus treatment market. | | Key Market Dynamics | Rising demand for innovative thrombus treatment solutions driven by regulatory changes and technological advancements in the GCC region. | | Countries Covered | GCC | ## Frequently Asked Questions **Q: What is the current valuation of the GCC thrombus treatment market?** A: The market valuation was $2013.5 Million in 2024. **Q: What is the projected market size for the GCC thrombus treatment market by 2035?** A: The projected valuation for 2035 is $4055.4 Million. **Q: What is the expected CAGR for the GCC thrombus treatment market during the forecast period 2025 - 2035?** A: The expected CAGR is 6.57% during the forecast period. **Q: Which companies are the key players in the GCC thrombus treatment market?** A: Key players include Bayer AG, Bristol-Myers Squibb Company, Johnson & Johnson, Roche Holding AG, Sanofi S.A., AstraZeneca PLC, Pfizer Inc., and Merck & Co., Inc. **Q: What are the main segments of the GCC thrombus treatment market?** A: The main segments are Atrial Thrombus, Venous Thrombus, Medical Therapy, Surgery, and Others. **Q: What was the market size for Atrial Thrombus treatment in 2024?** A: The market size for Atrial Thrombus treatment was $1005.4 Million in 2024. **Q: What is the projected market size for Venous Thrombus treatment by 2035?** A: The projected market size for Venous Thrombus treatment is $2027.7 Million by 2035. **Q: How much is the Medical Therapy segment expected to grow by 2035?** A: The Medical Therapy segment is expected to grow to $2000.0 Million by 2035. **Q: What was the valuation of the Surgery segment in 2024?** A: The Surgery segment was valued at $800.0 Million in 2024. **Q: What is the expected growth for the Others segment by 2035?** A: The Others segment is projected to grow to $555.4 Million by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/gcc-thrombus-treatment-market-53601*